Summary

Eligibility
for males ages up to 7 months (full criteria)
Location
at UCLA
Dates
study started
study ends around
Principal Investigator
by Gerald S. Lipshutz, MD (ucla)
Headshot of Gerald S. Lipshutz
Gerald S. Lipshutz

Description

Summary

Ornithine Transcarbamylase (OTC) deficiency, the most common urea cycle disorder, is an inherited metabolic disorder caused by a genetic defect in a liver enzyme responsible for detoxification of ammonia. Individuals with OTC deficiency can build-up excess levels of ammonia in their blood, potentially resulting in devastating consequences, including cumulative and irreversible neurological damage, coma and death. The severe form of the condition emerges shortly after birth and is more common in boys than girls.

This is a Phase 1/2, open-label, multicenter, safety and dose finding study of ECUR-506 in male babies with neonatal onset OTC deficiency. The primary objective of this study is to evaluate the safety and tolerability of multiple dose levels of ECUR-506 following intravenous (IV) administration of a single dose.

Official Title

A Phase I/II First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of a Single Intravenous (IV) Administration of ECUR-506 in Males Less Than 9 Months of Age With Genetically Confirmed Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency

Details

The study drug, ECUR-506, is an investigational gene editing therapy. Gene editing is a way to repair, replace, or introduce new copies of genes that don't work. The study drug contains a working copy of the OTC gene that will be delivered by an IV infusion. It also contains a gene to encode the editing enzyme which is the part of the study drug that can cut DNA so that the OTC gene can be inserted. The study drug was designed to introduce a working copy of the OTC gene and a gene to encode the editing enzyme. A gene cannot enter cells by itself, it needs a delivery mechanism to move the gene into the cells. In this study, a commonly used virus called adeno-associated virus (AAV) is used to enter the cells and deliver the genes.

Keywords

Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease, Ornithine Carbamoyltransferase Deficiency (Disorder), Urea Cycle Disorders, Inborn, Amino Acid Metabolism, Inborn Errors, Ammonia, Brain Diseases, Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Central Nervous System Diseases, Genetic Diseases, Inborn, Genetic Diseases, X-Linked, High Ammonia, Hyperammonemia, Inborn, Inborn Errors, Liver Disease, Liver Transplant, Metabolism, Metabolic Diseases, Metabolism, Inborn Errors, Neonatal, Nervous System Diseases, NH4, Ornithine, OTC, OTC Deficiency, OTCD, Transcarbamylase, UCD, Urea Cycle Disorders, X-Linked, Inborn Urea Cycle Disorders, Ornithine Carbamoyltransferase Deficiency Disease, Deficiency Diseases, ECUR-506

Eligibility

Locations

  • UCLA Mattel Children's Hospital accepting new patients
    Los Angeles California 90095 United States
  • Children's Hospital of Colorado, Anshutz Medical Campus accepting new patients
    Aurora Colorado 80045 United States

Lead Scientist at University of California Health

  • Gerald S. Lipshutz, MD (ucla)
    Dr. Gerald Lipshutz holds the Joan S. and Ralph N. Goldwyn Chair in Immunobiology and Transplantation Research.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
iECURE, Inc.
ID
NCT06255782
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
Expecting 13 study participants
Last Updated